CS 01
Alternative Names: CS-01Latest Information Update: 23 Dec 2025
At a glance
- Originator CelSiege Biosciences
- Class Cancer vaccines; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Non-small cell lung cancer
Most Recent Events
- 22 Dec 2025 CelSiege Biosciences plans a phase I/II trial in Non-small cell lung cancer (Metastatic disease; Second-line therapy or greater)
- 22 Oct 2025 Adverse events and pharmacodynamics data from a preclinical studies in Non-small cell lung cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 (AACR-NCI-EORTC-2025)
- 22 Oct 2025 Preclinical trials in Non-small cell lung cancer in France (unspecified route)